149 related articles for article (PubMed ID: 31405688)
1. Effect of direct acting antiviral therapy of Chronic Hepatitis C virus on insulin resistance and Type2 DM in Egyptian patients (prospective study).
Boraie MB; Elnaggar YA; Ahmed MO; Mahmoud AM
Diabetes Metab Syndr; 2019; 13(4):2641-2646. PubMed ID: 31405688
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Glycated Haemoglobin (HbA1c) Level in Type 2 Diabetic Chronic HCV Non-cirrhotic Treatment-Naïve Egyptian Patients Eradicated with Sofosbuvir Plus Daclatasvir.
Hussein HA; Allam AS; Moaty ASA
Curr Diabetes Rev; 2020; 16(2):165-170. PubMed ID: 31146663
[TBL] [Abstract][Full Text] [Related]
3. INSULIN RESISTANCE REDUCTION AFTER SUSTAINED VIROLOGICAL RESPONSE WITH DIRECT ACTING ANTIVIRAL:NOT EVERY POPULATION IMPROVES.
Andrade VG; Yamashiro FDS; Oliveira CV; Moreira A; Winckler FC; Silva GF
Arq Gastroenterol; 2018; 55(3):274-278. PubMed ID: 30540091
[TBL] [Abstract][Full Text] [Related]
4. Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents.
Ciancio A; Bosio R; Bo S; Pellegrini M; Sacco M; Vogliotti E; Fassio G; Bianco Mauthe Degerfeld AGF; Gallo M; Giordanino C; Terzi di Bergamo L; Ribaldone D; Bugianesi E; Smedile A; Rizzetto M; Saracco GM
J Med Virol; 2018 Feb; 90(2):320-327. PubMed ID: 28960353
[TBL] [Abstract][Full Text] [Related]
5. Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients.
Cheng CH; Chu CY; Chen HL; Lin IT; Wu CH; Lee YK; Bair MJ
Front Endocrinol (Lausanne); 2021; 12():799382. PubMed ID: 35095765
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance.
Russo FP; Zanetto A; Gambato M; Bortoluzzi I; Al Zoairy R; Franceschet E; De Marchi F; Marzi L; Lynch EN; Floreani A; Farinati F; Schaefer B; Burra P; Zoller H; Mega A
J Viral Hepat; 2020 Feb; 27(2):188-194. PubMed ID: 31596996
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Hepatitis C Virus and Long-Term Effect on Glycemic Control.
Andres J; Barros M; Arutunian M; Zhao H
J Manag Care Spec Pharm; 2020 Jun; 26(6):775-781. PubMed ID: 32463777
[TBL] [Abstract][Full Text] [Related]
8. The impact of a successful treatment of hepatitis C virus on glyco-metabolic control in diabetic patients: a systematic review and meta-analysis.
Carnovale C; Pozzi M; Dassano A; D'Addio F; Gentili M; Magni C; Clementi E; Radice S; Fiorina P
Acta Diabetol; 2019 Mar; 56(3):341-354. PubMed ID: 30478781
[TBL] [Abstract][Full Text] [Related]
9. Insulin resistance as a predictor of early virologic response to HCV therapy among chronic HCV Egyptian patients.
Abd El-Wahab EW; Mikheal A; Sidkey F; Shatat HZ
J Med Virol; 2015 Mar; 87(3):428-40. PubMed ID: 25583244
[TBL] [Abstract][Full Text] [Related]
10. Impact of sustained virologic response on glucose parameters among patients with chronic hepatitis C treated with direct-acting antivirals.
Benetti F; de Araújo A; de Maman Júnior I; Coelho Borges Cheinquer C; Herz Wolff F; Cheinquer H
Arch Endocrinol Metab; 2024 May; 68():e220480. PubMed ID: 38709148
[TBL] [Abstract][Full Text] [Related]
11. Effect of treatment with direct antiviral agents (DAAs) on glycemic control in patients with type 2 diabetes mellitus & hepatitis C virus genotype 4.
Zied HY; Abo Alnasr NM; El-Bendary AS; Abd-Elsalam S; Hagag RY
Diabetes Metab Syndr; 2020; 14(4):679-682. PubMed ID: 32438332
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients.
Adinolfi LE; Nevola R; Guerrera B; D'Alterio G; Marrone A; Giordano M; Rinaldi L
J Gastroenterol Hepatol; 2018 Jul; 33(7):1379-1382. PubMed ID: 29228501
[TBL] [Abstract][Full Text] [Related]
13. Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment.
Elhelbawy M; Abdel-Razek W; Alsebaey A; Hashim M; Elshenawy H; Waked I
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):16-23. PubMed ID: 30024489
[TBL] [Abstract][Full Text] [Related]
14. Direct-acting antiviral agents decrease haemoglobin A1c level in patients with diabetes infected with hepatitis C virus: A systematic review & meta-analysis.
Lapumnuaypol K; Pisarcik D; Putthapiban P; Sukhumthammarat W; Wijarnpreecha K; Thongprayoon C; Ungprasert P
Indian J Med Res; 2020 Dec; 152(6):562-567. PubMed ID: 34145095
[TBL] [Abstract][Full Text] [Related]
15. Enhanced immune responses, PI3K/AKT and JAK/STAT signaling pathways following hepatitis C virus eradication by direct-acting antiviral therapy among Egyptian patients: a case control study.
Ramadan HK; Badr G; Ramadan NK; Sayed A
Pathog Dis; 2021 Mar; 79(3):. PubMed ID: 33524139
[TBL] [Abstract][Full Text] [Related]
16. The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents.
Huang JF; Huang CF; Yeh ML; Dai CY; Hsieh MH; Yang JF; Huang CI; Lin YH; Liang PC; Lin ZY; Chen SC; Yu ML; Chuang WL
Kaohsiung J Med Sci; 2017 Nov; 33(11):567-571. PubMed ID: 29050674
[TBL] [Abstract][Full Text] [Related]
17. Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study.
Lee H; Chien RN; Pao LH; Kuo CJ; Huang PH; Chang ML
Cells; 2021 Oct; 10(11):. PubMed ID: 34831156
[TBL] [Abstract][Full Text] [Related]
18. Impact of hepatitis C virus eradication with direct-acting antivirals on glycidic metabolism.
Sparvoli JMH; Sparvoli AC; de Carvalho Dumith S; Pereira AA; de Paula ALM; Garcia L; Belarmino V; da Hora VP; de Martínez AMB; Gonçalves CV
Arch Endocrinol Metab; 2023 Mar; 67(3):314-322. PubMed ID: 36468927
[TBL] [Abstract][Full Text] [Related]
19. Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication - comparison of the new direct-acting antiviral agents with the old regimens.
Carvalho JR; Velosa J; Serejo F
Scand J Gastroenterol; 2018; 53(7):857-863. PubMed ID: 29779403
[TBL] [Abstract][Full Text] [Related]
20. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection.
Petta S; Cammà C; Di Marco V; Cabibi D; Ciminnisi S; Caldarella R; Licata A; Massenti MF; Marchesini G; Craxì A
Antivir Ther; 2009; 14(5):631-9. PubMed ID: 19704165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
